Expression of miR‑542‑3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways

Li,Zhen; Yao,Jian‑Ni; Huang,Wen‑Ting; He,Rong‑Quan; Ma,Jie; Chen,Gang; Wei,Qing‑Jun

doi:10.3892/mmr.2018.9761

Expression of miR‑542‑3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways

Authors:
- Zhen Li
- Jian‑Ni Yao
- Wen‑Ting Huang
- Rong‑Quan He
- Jie Ma
- Gang Chen
- Qing‑Jun Wei
View Affiliations

Affiliations: Department of Orthopedic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, First Clinical Medical College of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
Published online on: December 13, 2018 https://doi.org/10.3892/mmr.2018.9761
Pages: 974-983
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is the most common pediatric primary bone tumor, with high malignancy rates and a poor prognosis following metastasis. At present, the role of microRNA (miR)‑542‑3p in OS remains to be elucidated. The purpose of the present study was to investigate the expression level of miR‑542‑3p in OS, and its potential molecular mechanisms, via a bioinformatics analysis. First, the expression of miR‑542‑3p in OS based on the continuous variables of the Gene Expression Omnibus database and PubMed was studied. Subsequently, the potential target genes of miR‑542‑3p were predicted using gene expression profiles and bioinformatics software. On the basis of the Database for Annotation, Visualization and Integrated Discovery, version 6.8, a study of gene ontology (GO) enrichment and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway knowledge base was conducted to explore the biological value of miR‑542‑3p in OS. Finally, the protein‑protein interaction (PPI) network was completed using the STRING database. The expression of miR‑542‑3p in OS was revealed to be significantly higher compared with that in normal tissue. In total, 1,036 target genes of miR‑542‑3p were obtained. The results of the GO enrichment analysis revealed that the significant terms were ‘bone development’, ‘cell cycle arrest’ and ‘intracellular signal transduction’. The results of the KEGG analysis revealed the highlighted pathways that were targeted to miR‑542‑3p, including the sphingolipid signaling pathway (P=3.91x10‑5), the phosphoinositide 3‑kinase (PI3K)‑AKT serine/threonine kinase (AKT) signaling pathway (P=3.17x10‑5) and the insulin signaling pathway (P=1.04x10‑5). The PPI network revealed eight hub genes: Ubiquitin‑60S ribosomal protein L40, Ras‑related C3 botulinum toxin substrate, mitogen‑activated protein kinase 1, epidermal growth factor receptor, cystic fibrosis transmembrane conductance regulator, PI3K regulatory subunit 1, AKT1, and actin‑related protein 2/3 complex subunit 1A, which may be the key target genes of miR‑542‑3p in OS. Taken together, these results have demonstrated that miR‑542‑3p was overexpressed in OS. The potential target genes and biological functions of miR‑542‑3p may provide novel insights into the differentially expressed genes that are involved in OS.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Meazza C and Scanagatta P: Metastatic osteosarcoma: A challenging multidisciplinary treatment. Expert Rev Anticancer Ther. 16:543–556. 2016. View Article : Google Scholar : PubMed/NCBI
3	Venkatramani R, Murray J, Helman L, Meyer W, Hicks MJ, Krance R, Lau C, Jo E and Chintagumpala M: Risk-based therapy for localized osteosarcoma. Pediatr Blood Cancer. 63:412–417. 2016. View Article : Google Scholar : PubMed/NCBI
4	Zhang Y, Wang Z and Gemeinhart RA: Progress in microRNA delivery. J Control Release. 172:962–974. 2013. View Article : Google Scholar : PubMed/NCBI
5	Hammond SM: An overview of microRNAs. Adv Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
6	Lages E, Ipas H, Guttin A, Nesr H, Berger F and Issartel JP: MicroRNAs: Molecular features and role in cancer. Front Biosci (Landmark Ed). 17:2508–2540. 2012. View Article : Google Scholar : PubMed/NCBI
7	Connett P: Water fluoridation: Is fluoride chemophobia? Br Dent J. 222:323–324. 2017. View Article : Google Scholar : PubMed/NCBI
8	Li Y, Zhang J, Zhang L, Si M, Yin H and Li J: Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of osteosarcoma cells by switching on suppressor microRNAs and inactivating of Notch-1 signaling. Carcinogenesis. 34:1601–1610. 2013. View Article : Google Scholar : PubMed/NCBI
9	Althoff K, Lindner S, Odersky A, Mestdagh P, Beckers A, Karczewski S, Molenaar JJ, Bohrer A, Knauer S, Speleman F, et al: miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating survivin. Int J Cancer. 136:1308–1320. 2015. View Article : Google Scholar : PubMed/NCBI
10	Cai J, Zhao J, Zhang N, Xu X, Li R, Yi Y, Fang L, Zhang L, Li M, Wu J and Zhang H: MicroRNA-542-3p suppresses tumor cell invasion via targeting AKT pathway in human astrocytoma. J Biol Chem. 290:24678–24688. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhang J, Wang S, Han F, Li J, Yu L, Zhou P, Chen Z, Xue S, Dai C and Li Q: MicroRNA-542-3p suppresses cellular proliferation of bladder cancer cells through post-transcriptionally regulating survivin. Gene. 579:146–152. 2016. View Article : Google Scholar : PubMed/NCBI
12	Shen X, Si Y, Yang Z, Wang Q, Yuan J and Zhang X: MicroRNA-542-3p suppresses cell growth of gastric cancer cells via targeting oncogene astrocyte-elevated gene-1. Med Oncol. 32:3612015. View Article : Google Scholar : PubMed/NCBI
13	Li H, Liu H, Pei J, Wang H and Lv H: miR-542-3p overexpression is associated with enhanced osteosarcoma cell proliferation and migration ability by targeting Van Gogh-like 2. Mol Med Rep. 11:851–856. 2015. View Article : Google Scholar : PubMed/NCBI
14	Wang Y, Huang JW, Castella M, Huntsman DG and Taniguchi T: p53 is positively regulated by miR-542-3p. Cancer Res. 74:3218–3227. 2014. View Article : Google Scholar : PubMed/NCBI
15	Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, et al: Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 343:d40022011. View Article : Google Scholar : PubMed/NCBI
16	Liu B, Li J, Zheng M, Ge J, Li J and Yu P: MiR-542-3p exerts tumor suppressive functions in non-small cell lung cancer cells by upregulating FTSJ2. Life Sci. 188:87–95. 2017. View Article : Google Scholar : PubMed/NCBI
17	Tao J, Liu Z, Wang Y, Wang L, Yao B, Li Q, Wang C, Tu K and Liu Q: MiR-542-3p inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting UBE3C. Biomed Pharmacother. 93:420–428. 2017. View Article : Google Scholar : PubMed/NCBI
18	Rang Z, Yang G, Wang YW and Cui F: miR-542-3p suppresses invasion and metastasis by targeting the proto-oncogene serine/threonine protein kinase, PIM1, in melanoma. Biochem Biophys Res Commun. 474:315–320. 2016. View Article : Google Scholar : PubMed/NCBI
19	Salinas-Souza C, De Andrea C, Bihl M, Kovac M, Pillay N, Forshew T, Gutteridge A, Ye H, Amary MF, Tirabosco R, et al: GNAS mutations are not detected in parosteal and low-grade central osteosarcomas. Mod Pathol. 28:1336–1342. 2015. View Article : Google Scholar : PubMed/NCBI
20	Yang Z, Chen Y, Fu Y, Yang Y, Zhang Y, Chen Y and Li D: Meta-analysis of differentially expressed genes in osteosarcoma based on gene expression data. BMC Med Genet. 15:802014. View Article : Google Scholar : PubMed/NCBI
21	Seong BK, Lau J, Adderley T, Kee L, Chaukos D, Pienkowska M, Malkin D, Thorner P and Irwin MS: SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization. Oncogene. 34:3582–3592. 2015. View Article : Google Scholar : PubMed/NCBI
22	Geng S, Gu L, Ju F, Zhang H, Wang Y, Tang H, Bi Z and Yang C: MicroRNA-224 promotes the sensitivity of osteosarcoma cells to cisplatin by targeting Rac1. J Cell Mol Med. 20:1611–1619. 2016. View Article : Google Scholar : PubMed/NCBI
23	Tan ML, Shao P, Friedhuber AM, van Moorst M, Elahy M, Indumathy S, Dunstan DE, Wei Y and Dass CR: The potential role of free chitosan in bone trauma and bone cancer management. Biomaterials. 35:7828–7838. 2014. View Article : Google Scholar : PubMed/NCBI
24	Li H, He Y, Hao P and Liu P: Identification of characteristic gene modules of osteosarcoma using bioinformatics analysis indicates the possible molecular pathogenesis. Mol Med Rep. 15:2113–2119. 2017. View Article : Google Scholar : PubMed/NCBI
25	Kovacs E, Zorn JA, Huang Y, Barros T and Kuriyan J: A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem. 84:739–764. 2015. View Article : Google Scholar : PubMed/NCBI
26	Biscaglia F, Rajendran S, Conflitti P, Benna C, Sommaggio R, Litti L, Mocellin S, Bocchinfuso G, Rosato A, Palleschi A, et al: Enhanced EGFR targeting activity of plasmonic nanostructures with engineered GE11 peptide. Adv Healthc Mater. 6:2017.doi: 10.1002/adhm.201700596. View Article : Google Scholar : PubMed/NCBI
27	Hou CH, Lin FL, Tong KB, Hou SM and Liu JF: Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway. Biochem Pharmacol. 89:453–463. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zhang T, Li J, Yin F, Lin B, Wang Z, Xu J, Wang H, Zuo D, Wang G, Hua Y and Cai Z: Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3. Oncogene. 36:6627–6639. 2017. View Article : Google Scholar : PubMed/NCBI
29	Tang F, Wang Y, Hemmings BA, Rüegg C and Xue G: PKB/Akt-dependent regulation of inflammation in cancer. Semin Cancer Biol. 48:62–69. 2018. View Article : Google Scholar : PubMed/NCBI
30	Zhu YR, Zhou XZ, Zhu LQ, Yao C, Fang JF, Zhou F, Deng XW and Zhang YQ: The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models. Oncotarget. 7:49527–49538. 2016.PubMed/NCBI
31	Han XG, Li Y, Mo HM, Li K, Lin D, Zhao CQ, Zhao J and Tang TT: TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances. Tumour Biol. 37:8857–8867. 2016. View Article : Google Scholar : PubMed/NCBI
32	Zucchini C, Manara MC, Pinca RS, De Sanctis P, Guerzoni C, Sciandra M, Lollini PL, Cenacchi G, Picci P, Valvassori L and Scotlandi K: CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. Oncogene. 33:1912–1921. 2014. View Article : Google Scholar : PubMed/NCBI
33	Siegel DH, Cottrell CE, Streicher JL, Schilter KF, Basel DG, Baselga E, Burrows PE, Ciliberto HM, Vigh-Conrad KA, Eichenfield LF, et al: Analyzing the genetic spectrum of vascular anomalies with overgrowth via cancer genomics. J Invest Dermatol. 138:957–967. 2018. View Article : Google Scholar : PubMed/NCBI
34	Jiang ZH, Peng J, Yang HL, Fu XL, Wang JZ, Liu L, Jiang JN, Tan YF and Ge ZJ: Upregulation and biological function of transmembrane protein 119 in osteosarcoma. Exp Mol Med. 49:e3292017. View Article : Google Scholar : PubMed/NCBI
35	Liu Z, Piao L, Zhuang M, Qiu X, Xu X, Zhang D, Liu M and Ren D: Silencing of histone methyltransferase NSD3 reduces cell viability in osteosarcoma with induction of apoptosis. Oncol Rep. 38:2796–2802. 2017. View Article : Google Scholar : PubMed/NCBI
36	Guzman-Perez V, Bumke-Vogt C, Schreiner M, Mewis I, Borchert A and Pfeiffer AF: Benzylglucosinolate derived isothiocyanate from tropaeolum majus reduces gluconeogenic gene and protein expression in human cells. PLoS One. 11:e01623972016. View Article : Google Scholar : PubMed/NCBI
37	Guan H, Tan P, Xie L, Mi B, Fang Z, Li J, Yue J, Liao H and Li F: FOXO1 inhibits osteosarcoma oncogenesis via Wnt/β-catenin pathway suppression. Oncogenesis. 4:e1662015. View Article : Google Scholar : PubMed/NCBI
38	Dasgupta B and Chhipa RR: Evolving lessons on the complex role of AMPK in normal physiology and cancer. Trends Pharmacol Sci. 37:192–206. 2016. View Article : Google Scholar : PubMed/NCBI
39	Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, Qiu B, Li Y, Guo L, Wu M, et al: Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res. 19:5372–5380. 2013. View Article : Google Scholar : PubMed/NCBI
40	Cho SY, Lee HJ, Lee HJ, Jung DB, Kim H, Sohn EJ, Kim B, Jung JH, Kwon BM and Kim SH: Activation of AMP-activated protein kinase α and extracelluar signal-regulated kinase mediates CB-PIC-induced apoptosis in hypoxic SW620 colorectal cancer cells. Evid Based Complement Alternat Med. 2013:9743132013. View Article : Google Scholar : PubMed/NCBI
41	Zhao Z, Yin JQ, Wu MS, Song G, Xie XB, Zou C, Tang Q, Wu Y, Lu J, Wang Y, et al: Dihydromyricetin activates AMP-activated protein kinase and P38(MAPK) exerting antitumor potential in osteosarcoma. Cancer Prev Res (Phila). 7:927–938. 2014. View Article : Google Scholar : PubMed/NCBI
42	Hu K, Dai HB and Qiu ZL: mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review). Oncol Rep. 36:1219–1225. 2016. View Article : Google Scholar : PubMed/NCBI
43	Kureel J, Dixit M, Tyagi AM, Mansoori MN, Srivastava K, Raghuvanshi A, Maurya R, Trivedi R, Goel A and Singh D: miR-542-3p suppresses osteoblast cell proliferation and differentiation, targets BMP-7 signaling and inhibits bone formation. Cell Death Dis. 5:e10502014. View Article : Google Scholar : PubMed/NCBI